DPP4 and Hypertension: Furthermore, in a meta-analysis of 10 randomized controlled trials, SGLT2i have demonstrated superiority over dipeptidyl peptidase-4 (DPP-4) inhibitors, one of the most commonly used antidiabetic agents, in reducing the risk of incident hypertension in patients with diabetes without prior known diagnostic of hypertension, suggesting a better potential preventive role than DPP-4 inhibitors use (66).